{"entity":{"id":"nct06759090","kind":"trial","name":"Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of camrelizumab in pancreatic cancer, run by Zhejiang University, not yet recruiting.","summary":"Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT06759090 by Zhejiang University, with a registry enrolment figure of 43 participants, started 2025-01-15 and due to reach its primary completion in 2027-01-15. Interventions recorded: Metronomic capecitabine; Camrelizumab; Apatinib Mesylate Tablets. Conditions listed: Metastatic Pancreatic Carcinoma. Primary outcome: Objective Response Rate (ORR); Disease Control Rate (DCR); Safety of treatment. Pancreatic eligibility wording from the registry: \"* 1: Age is 18 years or older; 2: Pathologically confirmed pancreatic adenocarcinoma; 3: As determined by the investigator, second-line treatment for advanced pancreatic cancer has failed; or the patient has a poor performance status (PS score \\>1), and the investigator considers that the patient ca\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06759090","url":"https://clinicaltrials.gov/study/NCT06759090"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["camrelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06759090","phase":"2","setting":"Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate in Advanced Pancreatic Cancer：A Multi-center, Single-arm, Phase II Exploratory Trial","sponsor":"Zhejiang University","participation":[{"nct":"NCT06759090","source":"https://clinicaltrials.gov/study/NCT06759090","fetchedAt":"2026-10-07T16:55:00.061Z","studySha256":"50bd4cb1fcc8fe0a09ca04aba94c6da9ee4e5c1fe932f3c091b54704cf325f4b","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2025-01-06","leadSponsor":"Zhejiang University","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":43,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2025-01-15","startedType":"estimated","enrolled":43,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06759090/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}